These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20937788)

  • 41. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Basic mechanisms of chemotherapy.
    Mitchison DA
    Chest; 1979 Dec; 76(6 Suppl):771-81. PubMed ID: 92392
    [No Abstract]   [Full Text] [Related]  

  • 45. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Present chemotherapy for tuberculosis.
    Dutt AK; Stead WW
    J Infect Dis; 1982 Nov; 146(5):698-704. PubMed ID: 6813386
    [No Abstract]   [Full Text] [Related]  

  • 47. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale for chemotherapy of tuberculosis and current recommendations.
    Kumar L
    Indian Pediatr; 1992 Nov; 29(11):1337-9. PubMed ID: 1294486
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
    Lenaerts AM; Chase SE; Cynamon MH
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3167-8. PubMed ID: 11036043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
    Grosset J; Truffot-Pernot C; Lacroix C; Ji B
    Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5567-9. PubMed ID: 24936590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.
    Ahmad Z; Fraig MM; Pinn ML; Tyagi S; Nuermberger EL; Grosset JH; Karakousis PC
    J Antimicrob Chemother; 2011 Jul; 66(7):1560-6. PubMed ID: 21602551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Present status of chemotherapy for tuberculosis.
    Grosset JH
    Rev Infect Dis; 1989; 11 Suppl 2():S347-52. PubMed ID: 2652251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tuberculosis].
    Lange C; Kalsdorf B; Maurer FP; Heyckendorf J
    Internist (Berl); 2019 Nov; 60(11):1155-1175. PubMed ID: 31641790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.